You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm expects full-year revenue growth of up to 39 percent, but fell short of prior guidance for the year.
The firm said that it delivered more than 29,990 test results in the third quarter of 2016 compared to 27,820 results delivered in Q3 2015.
The results showed overall high concordance between test results and whether patients received chemotherapy, with some relevant exceptions.
The Swiss firm's assay combines a 29-gene host immune response panel with two tumor-derived proteins to detect early-stage colorectal cancer and large adenomatous polyps.